Health & Biotech EZZ signs agreement with University of Auckland to conduct product research March 9, 2023 Special Report: EZZ has signed a contract for service agreement with the University of Auckland to conduct research on anti-aging… Louie the beagle is beating the odds thanks to PharmAust’s canine cancer trial March 9, 2023 Special Report: In PharmAust’s current Phase-2 study in the treatment of B-Cell Lymphoma in Canines with Monepantel (MPL) a 12-year-old… Q&A: Nanoveu’s new chairman Dr David Pevcic says the market opportunity for antifouling solar panel coatings is in the billions March 9, 2023 Antiviral technology company Nanoveu (ASX:NVU) has enjoyed some success with its antivral products, centred around the Nanoshield film that uses… ASX Health Stocks: Mesoblast share price jumps as FDA accepts resubmission for Remestemcel-L March 8, 2023 The US FDA has accepted Mesoblast's (ASX:MSB) biological licence resubmission for Remestemcel-L in the treatment of children with SR-aGVHD. Broker says EZZ share price could more than double as the company makes inroads into global markets March 8, 2023 Special Report: Lodge Partners says EZZ could be worth $1 from its current price of $0.42, as the company’s brands… As it awaits crucial FDA approval Botanix reckons Aussies have a penchant for backing high-risk companies March 8, 2023 Special Report: Botanix Pharmaceuticals chief operating officer Dr Howie McKibbon believes Aussie Investors are comfortable backing early-stage, high-risk companies which… PharmAust eyes Phase-3 trial after positive results from canine cancer drug March 7, 2023 Special Report: PharmAust says it’s Phase-2 trial for the treatment of canine B-cell Lymphoma with Monepantel (MPL) is expected to… ASX Health Stocks: Emyria partners with Pax Centre to provide psychedelics therapy for PTSD sufferers March 7, 2023 Emyria (ASX: EMD) has announced a collaboration with Pax to develop a scalable program to provide safe MDMA-assisted therapy for… Dr Boreham’s Crucible: Tag it and bag it – Bluechiip’s ready to come in from the cold March 7, 2023 But dare we say, Bluechiip now looks to be on the cusp of serious revenues and great fame and fortune… Argenica confirms safety of ARG-007 in Phase-1 trial, makes preparations for Phase-2 March 6, 2023 Special Report: The safety report released today has given Argenica the confidence to progress to the Phase-2 clinical trial in… Next» « Previous